Table 4.
Recommendations for the clinical management of drug-drug interactions between statins and direct-acting antivirals
| Harvoni(LED/SOF) | Epclusa (SOF/VEL) | Zepatier (EBR/GZR) | Maviret (GLP/PIB) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Atorvastatin |  |
 |
|
|
|
<20 mg/day |  |
||
| Fluvastatin | |
|
|
<20 mg/day | |
|
|||
| Lovastatin | |
|
|
|
<20 mg/day | |
|
||
| Pitavastatin | |
|
|
|
|||||
| Pravastatin | |
|
|
<20 mg/day | |||||
| Rosuvastatin | |
|
<10 mg/day | |
<10 mg/day | |
<10 mg/day | ||
| Simvastatin | |
|
|
|
|
<20 mg/day | |
|
|
|
:dose reduction (Not DAA) |
:monitoring myopathy |
:contraindication |
|||||||
No Interaction Expected Potential Interaction Do Not Coadminister DDIs: drug-drug interactions; DAAs: direct-acting antivirals; LED: ledipasvir; SOF: sofosbuvir; VEL: velpatasvir; EBR: elbasvir; GZR: grazoprevir; GLP: glecaprevir; PIB: pibrentasvir